Met interacts with EGFR and Ron in canine osteosarcoma

Veterinary and Comparative Oncology

Volumn 11, Issue 2, 2013, Pages 124-139

  McCleese, J K ^a   Bear, M D ^a   Kulp, S K ^a   Mazcko, C ^b   Khanna, C ^b   London, C A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cross talk; EGFR; Met; Osteosarcoma; Ron

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RON PROTEIN; SCATTER FACTOR; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

ANIMAL; ARTICLE; DOG; DOG DISEASE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 84877586941     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00309.x     Document Type: Article

References (55)

1. Mueller F, Fuchs B and Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Research 2007; 27: 155-164.
2. Krause DS and Van Etten RA. Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 2005; 353: 172-187.
3. Weiss A and Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998; 94: 277-280.
4. Ponzetto C, Bardelli A, Zhen Z, Maina F. dalla Zonca P, Giordano S, Graziani A, Panayotou G and Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-271.
5. Wada T, Qian XL and Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990; 61: 1339-1347.
6. Tartare S, Ballotti R and Van Obberghen E. Interaction between heterologous receptor tyrosine kinases. Hormone-stimulated insulin receptors activate unoccupied IGF-I receptors. FEBS Letters 1991; 295: 219-222.
7. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, Cooper JA and Kazlauskas A. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. Journal of Biological Chemistry 1991; 266: 8987-92.
8. Liao AT, McCleese J, Kamerling S, Christensen JG and London CA. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against canine osteosarcoma. Veterinary Comparative Oncology 2007; 5: 177-196.
9. Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC and Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Veterinary Pathology 2009; 46: 869-877.
10. Raffaella De M, Silvia M, Selina I, Martina O, Emanuela M, Andrea B, James GC, Bartolomeo B, Roy AL, Paolo B and Maria Flavia Di R. Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. The Journal of Pathology 2009; 218: 399-408.
11. Wagh PK, Peace BE and Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Advances Cancer Research 2008; 100: 1-33.
12. Comoglio PM and Boccaccio C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1996; 1: 347-354.
13. Lai AZ, Abella JV and Park M. Crosstalk in Met receptor oncogenesis. Trends in Cell Biology 2009; 19: 542-551.
14. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P and Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000; 19: 3041-3049.
15. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM and Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental Cell Research 2003; 288: 382-389.
16. Shattuck DL, Miller JK and Carraway KL III and Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research 2008; 68: 1471-1477.
17. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902.
18. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK and Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. The Journal of Biological Chemistry 2000; 275: 8806-8811.
19. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD and Comb MJ. Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 692-697.
20. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S and Laterra J. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Molecular Cancer Research 2008; 6: 139-150.
21. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA and Ma PC. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. British Journal of Cancer 2008; 99: 911-922.
22. Xu KP and Yu FS. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Investigative Ophthalmology and Visual Science 2007; 48: 2242-2248.
23. Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL and Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biology and Therapy 2007; 6: 561-570.
24. Ciardiello F and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research 2001; 7: 2958-2970.
25. Pedersen MW, Meltorn M, Damstrup L and Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Annals of Oncology 2001; 12: 745-760.
26. Bergstrom JD, Westermark B and Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Experimental Cell Research 2000; 259: 293-299.
27. Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Annals of Surgical Oncology 2005; 12: 273-81.
28. Do SI, Jung WW, Kim HS and Park YK. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. International Journal of Oncology 2009; 34: 797-803.
29. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G and Greco MA. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Human Pathology 2007; 38: 1184-1191.
30. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC and Khoury JD. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008; 113: 1453-1461.
31. Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, Bielack S and Buerger H. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clinical Cancer Research 2007; 13: 2998-3005.
32. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H, Pollak MN, Aparicio SA and Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Research 2010; 70: 8770-8781.
33. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM and Helman LJ. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clinical Cancer Research 2002; 8: 2406-2412.
34. Vail DM, Kurzman ID, Glawe PC, O'Brien MG, Chun R, Garrett LD, Obradovich JE and Fred RM III, Khanna C, Colbern GT and Working PK. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemotherapy and Pharmacology 2002; 50: 131-136.
35. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22: 27-55.
36. Dussault I and Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents in Medicinal Chemistry 2009; 9: 221-229.
37. Albanell J and Gascon P. Small molecules with EGFR-TK inhibitor activity. Current Drug Targets 2005; 6: 259-274.
38. Frampton JE and Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004; 64: 2475-2492.
39. Freeman BB III, Daw NC, Geyer JR, Furman WL and Stewart CF. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Investigation 2006; 24: 310-317.
40. Chun R and de Lorimier LP. Update on the biology and management of canine osteosarcoma. The Veterinary Clinics of North America. Small Animal Practice 2003; 33: 491-516. vi.
41. Dulak AM, Gubish CT, Stabile LP, Henry C and Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011; 30: 3625-3635.
42. Chen Q, Seol DW, Carr B and Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997; 26: 59-66.
43. Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS and Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. British Journal of Cancer 2005; 92: 1906-1914.
44. Santoro MM, Collesi C, Grisendi S, Gaudino G and Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Molecular and Cell Biology 1996; 16: 7072-7083.
45. Lee CT, Chow NH, Su PF, Lin SC, Lin PC and Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Diseases of the Colon and Rectum 2008; 51: 1268-1274.
46. Lee WY, Chen HH, Chow NH, Su WC, Lin PW and Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clinical Cancer Research 2005; 11: 2222-2228.
47. Puri N and Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. Journal of Carcinogenesis 2008; 7: 9.
48. Mueller KL, Hunter LA, Ethier SP and Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Research 2008; 68: 3314-3322.
49. Mueller KL, Yang ZQ, Haddad R, Ethier SP and Boerner JL. EGFR/Met association regulates EGFR TKI resistance in breast cancer. Journal of Molecular Signaling 2010; 5: 8.
50. Wada T and Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849.
51. Seidman R, Gitelman I, Sagi O, Horwitz SB and Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Experimental Cell Research 2001; 268: 84-92.
52. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR and Mossman BT. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Molecular Cancer 9: 314.
53. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
54. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH and Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 20932-20937.
55. McDermott U, Pusapati RV, Christensen JG, Gray NS and Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Research 2010; 70: 1625-1634.